How Does Vagus Nerve Stimulation Affect Blood Glucose, Food, and Movement Cravings?
1 other identifier
interventional
8
1 country
1
Brief Summary
The purpose of this study is to determine the feasibility of using non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) to examine physiological and psychological responses in a college-aged healthy population
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jul 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 3, 2026
CompletedFirst Posted
Study publicly available on registry
March 9, 2026
CompletedStudy Start
First participant enrolled
July 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2028
Study Completion
Last participant's last visit for all outcomes
May 1, 2028
May 20, 2026
May 1, 2026
1.8 years
March 3, 2026
May 18, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in plasma glucose
Hour 2 after oral glucose load
Study Arms (2)
Active taVNS
ACTIVE COMPARATORSham taVNS
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Participants must be between the ages of 18 and 35 as we are focused on recruiting undergraduate and graduate students.
You may not qualify if:
- Participants will be excluded if they have epilepsy, clinically significant tachycardia or arrhythmia, diabetes (Type 1 or Type 2) or another metabolic disease, current pregnancy, any implanted electronic medical device (for example, pacemaker or defibrillator), or a known skin allergy to adhesives that would prevent CGM placement. Participants will also be excluded if they have a history of major depressive disorder if taVNS could reasonably be expected to alter mood symptoms
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Minnesota Duluth
Duluth, Minnesota, 55812, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Mark Hartman, PhD
University of Minnesota
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 3, 2026
First Posted
March 9, 2026
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
May 1, 2028
Study Completion (Estimated)
May 1, 2028
Last Updated
May 20, 2026
Record last verified: 2026-05